Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.

about

LncRNA HOTTIP-Mediated HOXA11 Expression Promotes Cell Growth, Migration and Inhibits Cell Apoptosis in Breast Cancer.

P2860

Q50132069-89F44FCF-386E-4946-95BB-9BA94D59571A

P2860

Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.

Item

http://www.wikidata.org/entity/Q47671054

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Selective BCL-XL inhibition pr ...... pediatric glioblastoma cells.

@en

Selective BCL-XL inhibition pr ...... pediatric glioblastoma cells.

@nl

type

Item

label

Selective BCL-XL inhibition pr ...... pediatric glioblastoma cells.

@en

Selective BCL-XL inhibition pr ...... pediatric glioblastoma cells.

@nl

prefLabel

Selective BCL-XL inhibition pr ...... pediatric glioblastoma cells.

@en

Selective BCL-XL inhibition pr ...... pediatric glioblastoma cells.

@nl

P1154

2-s2.0-85041168152

http://www.w3.org/2001/XMLSchema#string

P1433

Neuro-Oncology

P1476

Selective BCL-XL inhibition pr ...... d pediatric glioblastoma cells

@en

P2093

Adam Davison

http://www.w3.org/2001/XMLSchema#string

Chunyong Ding

http://www.w3.org/2001/XMLSchema#string

Jane Levesley

http://www.w3.org/2001/XMLSchema#string

Jia Zhou

http://www.w3.org/2001/XMLSchema#string

Lynette Steele

http://www.w3.org/2001/XMLSchema#string

Sean Lawler

http://www.w3.org/2001/XMLSchema#string

P2860

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Structure-guided design of a selective BCL-X(L) inhibitor

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

ABT-263 enhances sensitivity to metformin and 2-deoxyglucose in pediatric glioma by promoting apoptotic cell death

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization.

Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.

Aurora kinase inhibition induces PUMA via NF-κB to kill colon cancer cells.

P304

203-214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOX134

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Susan C. Short

Anke Brüning-Richardson

P5530

27297484

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090733904

http://www.w3.org/2001/XMLSchema#string

P698

29016820

http://www.w3.org/2001/XMLSchema#string

P921

medulloblastoma

P932

7059858

http://www.w3.org/2001/XMLSchema#string

P953

129545